Literature DB >> 9525287

p53, but not p16 mutations in oral squamous cell carcinomas are associated with specific CYP1A1 and GSTM1 polymorphic genotypes and patient tobacco use.

P Lazarus1, S N Sheikh, Q Ren, S P Schantz, J C Stern, J P Richie, J Y Park.   

Abstract

Inactivation of tumor suppressor genes like p53 and p16 play a key role in tumor progression, with a high incidence of mutations existing for both genes in oral squamous cell carcinomas. Previous studies have demonstrated, (i) a correlation between the prevalence of p53 mutations and tobacco use [Brennan et al. (1995) New Engl. J. Med., 332, 712-717; Lazarus et al. (1996) Carcinogenesis, 17, 733-739], and (ii) a link between genotypes in specific xenobiotic metabolizing enzymes and oral cancer susceptibility [Park et al. (1997) Cancer Epid. Biomarkers Prev., 6, 791-797). In this paper, we present results of our examination of a series of 80 oral squamous cell carcinomas for p53 exons 5-9 and p16 exons 1-2 mutations, and the potential association of these mutations with specific genotyping patterns. p53 mutation prevalence in oral tumors was linked with increased patient tobacco use using several stratification criteria. There was a significantly higher prevalence of p53 mutations in OCSCCs from patients who smoked > 30 pack-years as compared to tumors from patients who smoked < or = 30 pack-years (OR = 2.8; CI = 1.1-7.2). No significant association was observed with patient alcohol consumption. There was a significant association between the prevalence of p53 mutations in oral tumors and CYP1A1 genotyping patterns in these oral cancer patients, with the highest p53 mutation prevalence observed in subjects with the CYP1A1 [val]/GSTM1 [+] genotype (OR = 6.0; CI = 1.2-29.7). A significant association was not observed between the prevalence of p16 mutations in oral tumors and tobacco use, or CYP1A1 [val] or GSTM1 (0/0) genotypes. These data suggest that the induction of mutations in specific tumor suppressor genes or oncogenes in oral tumors may be associated with specific carcinogen exposures, and that this association may be linked to specific polymorphic genotypes in xenobiotic-metabolizing enzyme genes.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9525287     DOI: 10.1093/carcin/19.3.509

Source DB:  PubMed          Journal:  Carcinogenesis        ISSN: 0143-3334            Impact factor:   4.944


  7 in total

1.  Association of p53 genomic instability with the glutathione S-transferase null genotype in gastric cancer in the Portuguese population.

Authors:  A R Conde; G Martins; C Saraiva; J Rueff; C Monteiro
Journal:  Mol Pathol       Date:  1999-06

2.  Contrasting effects of an Mdm2 functional polymorphism on tumor phenotypes.

Authors:  G J Ortiz; Y Li; S M Post; V Pant; S Xiong; C A Larsson; A K El-Naggar; D G Johnson; G Lozano
Journal:  Oncogene       Date:  2017-09-18       Impact factor: 9.867

3.  GSTM1, GSTT1, GSTP1 and CYP1A1 genetic polymorphisms and susceptibility to esophageal cancer in a French population: different pattern of squamous cell carcinoma and adenocarcinoma.

Authors:  Ahmed Abbas; Karine Delvinquiere; Mathilde Lechevrel; Pierre Lebailly; Pascal Gauduchon; Guy Launoy; François Sichel
Journal:  World J Gastroenterol       Date:  2004-12-01       Impact factor: 5.742

4.  Cytochrome P450 1A1 Ile462Val polymorphism and oral carcinoma risk: an updated meta-analysis including 1,515 cases and 2,233 controls.

Authors:  Xianlu Zhuo; Houyu Zhao; Aoshuang Chang; Huiping Ye; Yan Zhou; Yufeng Song; Yinghui Tan
Journal:  Tumour Biol       Date:  2012-07-31

Review 5.  Cancer risk assessment, indicators, and guidelines for polycyclic aromatic hydrocarbons in the ambient air.

Authors:  Carl-Elis Boström; Per Gerde; Annika Hanberg; Bengt Jernström; Christer Johansson; Titus Kyrklund; Agneta Rannug; Margareta Törnqvist; Katarina Victorin; Roger Westerholm
Journal:  Environ Health Perspect       Date:  2002-06       Impact factor: 9.031

6.  Repression of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) but not its receptors during oral cancer progression.

Authors:  Nadarajah Vigneswaran; Darryl C Baucum; Jean Wu; Yahuan Lou; Jerry Bouquot; Susan Muller; Wolfgang Zacharias
Journal:  BMC Cancer       Date:  2007-06-25       Impact factor: 4.430

7.  Assessment of immunohistochemical expression of p16 in head and neck squamous cell carcinoma and their correlation with clinicopathological parameters.

Authors:  Pinki Pandey; Megha Ralli; Alok Dixit; Savita Agarwal; Vineet Chaturvedi; Anshul Sawhney; Roopak Agarwal
Journal:  J Oral Maxillofac Pathol       Date:  2021-05-14
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.